Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAMS for Venous Ulcers
NCT05962931Phase 2Unknown
- Sponsor
- Red Andaluza de Terapias Avanzadas
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Bioengineered Artificial Mesenchymal Sheet in venous ulcer (2 arms), sponsored by Red Andaluza de Terapias Avanzadas. Primary endpoints: Feasibility of Bioengineered Artificial Mesenchymal Sheet at 1 year and Safety of Bioengineered Artificial Mesenchymal Sheet at 1 year. Status: unknown.
02
Drugs
Bioengineered Artificial Mesenchymal Sheet
03
Conditions
venous ulcer
Beyond the preview
Go deeper on NCT05962931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962931.